I M Stratton

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi How to ensure your paper is rejected by the statistical reviewer
    I M Stratton
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK
    Diabet Med 22:371-3. 2005
  2. ncbi Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
    I M Stratton
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE
    BMJ 321:405-12. 2000
  3. ncbi Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group
    S E Manley
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
    Diabet Med 17:518-23. 2000
  4. ncbi UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
    I M Stratton
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
    Diabetologia 44:156-63. 2001
  5. ncbi The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
    R J Stevens
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Clin Sci (Lond) 101:671-9. 2001
  6. ncbi Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
    I M Stratton
    Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford OX3 7LJ, UK
    Diabetologia 49:1761-9. 2006
  7. ncbi Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67)
    A I Adler
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK
    Diabet Med 22:306-11. 2005
  8. ncbi Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
    R R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford, UK
    Diabetologia 52:50-9. 2009
  9. ncbi A method for assessing quality of control from glucose profiles
    N R Hill
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK
    Diabet Med 24:753-8. 2007
  10. ncbi A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
    P M Clarke
    Health Economics Research Centre, Department of Public Health, University of Oxford, Headington, Oxford, UK
    Diabetologia 47:1747-59. 2004

Detail Information

Publications15

  1. ncbi How to ensure your paper is rejected by the statistical reviewer
    I M Stratton
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK
    Diabet Med 22:371-3. 2005
  2. ncbi Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
    I M Stratton
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE
    BMJ 321:405-12. 2000
    ..To determine the relation between exposure to glycaemia over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes...
  3. ncbi Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group
    S E Manley
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
    Diabet Med 17:518-23. 2000
    ..To assess the effect of diet on fasting plasma lipids and lipoproteins in patients with newly diagnosed Type 2 diabetes...
  4. ncbi UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
    I M Stratton
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
    Diabetologia 44:156-63. 2001
    ..CONCLUSION/INTERPRETATION: The findings re-emphasise the need for good glycaemic control and assiduous treatment of hypertension if diabetic retinopathy is to be minimised...
  5. ncbi The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
    R J Stevens
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Clin Sci (Lond) 101:671-9. 2001
    ..001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes...
  6. ncbi Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
    I M Stratton
    Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford OX3 7LJ, UK
    Diabetologia 49:1761-9. 2006
    ..Intensive treatment of both these risk factors is required to minimise the incidence of complications...
  7. ncbi Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67)
    A I Adler
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK
    Diabet Med 22:306-11. 2005
    ..Whether insulin sensitivity measured after diagnosis of diabetes is associated with incident cardiovascular disease was evaluated in this prospective study...
  8. ncbi Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
    R R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford, UK
    Diabetologia 52:50-9. 2009
    ....
  9. ncbi A method for assessing quality of control from glucose profiles
    N R Hill
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK
    Diabet Med 24:753-8. 2007
    ....
  10. ncbi A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
    P M Clarke
    Health Economics Research Centre, Department of Public Health, University of Oxford, Headington, Oxford, UK
    Diabetologia 47:1747-59. 2004
    ....
  11. ncbi Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes
    D S Powell
    Diabetes Research Laboratories, Oxford Centre for Diabetes Endocrinology and Metabolism, Radcliffe Infirmary, UK
    Diabetes Res Clin Pract 60:105-10. 2003
    ..It is unlikely that the common polymorphisms for the ApoE gene are linked to amyloid formation or progression of islet dysfunction in Type 2 diabetes...
  12. ncbi Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70)
    T M E Davis
    University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, P.O. Box 480, Fremantle, Western Australia, 6959, Australia
    Diabetologia 48:695-702. 2005
    ..0001). CONCLUSIONS/INTERPRETATION: Autoantibody-positive patients can be treated initially with sulphonylurea, but are likely to require insulin earlier than autoantibody-negative patients...
  13. ncbi Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52)
    E M Kohner
    Department of Medicine, St. Thomas' Hospital, London, UK
    Diabet Med 18:178-84. 2001
    ..CONCLUSION: Few type 2 diabetic patients without retinopathy progress to photocoagulation in the following 3-6 years, while patients with more severe retinopathy lesions need to be monitored closely...
  14. ncbi Analysis of the hexokinase II gene in subjects with insulin resistance and NIDDM and detection of a Gln142-->His substitution
    A Vidal-Puig
    Charles A Dana Research Institute and Harvard Thorndike Laboratory of Beth Israel Hospital, Boston, Massachusetts
    Diabetes 44:340-6. 1995
    ..SSCP variants detected in PCR products containing exons 5, 10, and 17 were due to single base substitutions in flanking intronic sequences. A polymorphic GGA repeat was identified within intron 5.(ABSTRACT TRUNCATED AT 250 WORDS)..
  15. ncbi Recommendations for designing tables that report randomized trials
    E S Johnson
    Department of Pharmacy, Health Sciences Center, University of Washington, Seattle, WA 98195, USA
    Diabet Med 24:1309-12. 2007